A new NF-kappaB inhibitor attenuates a TH1 type immune response in a murine model.
Nuclear factor kappa B (NF-kappaB) plays a wide variety of pathophysiological roles and modulation of its pathway can be a good novel drug target. Here, we found that our recently synthesized NF-kappaB inhibitor attenuated an ovalbumin-specific delayed-type hypersensitivity response in vivo and suppressed production of IL-12 by dendritic cells and TH1 cytokines by T cells in vitro. These findings suggest that the activation of NF-kappaB mounts TH1 type immune responses, and that this new NF-kappaB inhibitor has a therapeutic potential in this context.
Kabashima
Kenji
K
Department of Dermatology, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. kaba@kuhp.kyoto-u.ac.jp
Honda
Tetsuya
T
Nunokawa
Youichi
Y
Miyachi
Yoshiki
Y
D000818:Animals; D002460:Cell Line; D003713:Dendritic Cells / Q000276:immunology; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000188:drug therapy / Q000276:immunology; D007189:Indans / Q000737:chemistry* / Q000378:metabolism* / Q000627:therapeutic use; D007249:Inflammation / Q000276:immunology; D018664:Interleukin-12 / Q000378:metabolism; D008213:Lymphocyte Activation; D051379:Mice; D008810:Mice, Inbred C57BL; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000276:immunology*; D012867:Skin / Q000276:immunology / Q000528:radiation effects; D018417:Th1 Cells / Q000276:immunology*; D014466:Ultraviolet Rays
C496224:DSKB-2 compound; D007189:Indans; D016328:NF-kappa B; D018664:Interleukin-12; C093582:indan